Moreover, although CALGB is part of the current prognostic assessment of malignant pleural mesothelioma, its design adjusts to classical therapeutic approaches and results inaccurate for emergent immunotherapy-based regimens, which demands the inclusion of immunological biomarkers, such as PD-L1. Here, CD274 is linked to malignant pleural mesothelioma.